

<b>CV Date</b>	06/12/2021
----------------	------------

## Part A. PERSONAL INFORMATION

First Name	Raquel		
Family Name	Tarazona Lafarga		
Sex	Female	Date of Birth	20/02/1962
ID number Social Security, Passport	05379349V		
URL Web			
Email Address	rtarazon@unex.es		
Open Researcher and Contributor ID (ORCID)	0000-0002-2926-6377		

### A.1. Current position

Job Title	Catedrático de Universidad (Full Professor)		
Starting date	2018		
Institution	Universidad de Extremadura		
Department / Centre	Fisiología, Unidad de Inmunología / Facultad de Veterinaria		
Country		Phone Number	
Keywords			

### A.2. Previous positions (Research Career breaks included)

Period	Job Title / Name of Employer / Country
2002 - 2002	Contrato Ramón y Cajal / Universidad de Córdoba
1999 - 2002	Contrato investigador FIS (equivalente actual Miguel Servet) / Hospital Universitario Reina Sofía, Córdoba
1996 - 1999	Contrato (Reincorporación) / Universidad de Córdoba
1995 - 1996	Contrato de investigador posdoctoral / National Institute for Medical Research, Londres
1993 - 1995	Marie Curie postdoctoral (UE) / National Institute for Medical Research, Londres
1988 - 1991	Beca predoctoral del MEC / Universidad Complutense, Madrid

### A.3. Education

Degree/Master/PhD	University / Country	Year
PhD in Medicine	Universidad Complutense de Madrid	1992
Medical Doctor, MD (Licenciado en Medicina y Cirugía)	Universidad Complutense de Madrid	1986

## Part B. CV SUMMARY

Raquel Tarazona Lafarga is Professor of Immunology at the University of Extremadura. Degree of Medicine at the Complutense University (1986). PhD at Complutense University (July of 1992). Predoctoral Fellowship for the Training of Research Staff of the Ministry of Science and Education (1987 to 1991) with 2 short stays at the Moredun Research Institute in Edinburgh. Marie Curie postdoc contract from the European Union (1993 to 1996) at the National Institute for Medical Research (Mill Hill) in London. In October 1996, she obtained a "Reincorporation Contract" from the Ministry of Education and Science (area of Immunology at the University of Córdoba). From 1999-2002 she obtained a FIS contracts for researchers, currently termed Miguel Servet contracts (Imunology, Reina Sofía University Hospital in Córdoba). In 2002 she obtained a "Ramón y Cajal" contract from the Ministry of Science and Technology in Spain. In the same year she obtained the position of "Professor Titular de Universidad" in Immunology and in August 2018 a Full Professor position at the University of Extremadura. Since 2000 and continuously to the present, she has been Principal Investigator of 6 projects

of national calls; 7 projects of the Autonomous Community of Extremadura and 4 agreements with companies. She is the coordinator of the Research Group "Tumor Immunopathology" from Junta de Extremadura.

She is co-author of 2 national patents (2222769 and 2198203) and one of European scope (Application Number: PCT/EP2012/054251). At the University of Córdoba she participated as a member of the research team led by Prof. Rafael Solana in three European calls, ImAginE and T-CIA (coordinated by Prof. Pawelec) and OISTER (coordinated by Prof. Schadendorf).

In recent years her research has focused on the analysis of the interactions between tumor cells and NK cells, analyzing inhibitory receptors such as TIGIT, TIM3, LAG3 and PD1 expressed on NK cells and cytokine-induced cytokine (CIK) cells in patients with acute myeloid leukemia (AML).

She has a positive evaluation of 5 six-year research periods (1990-2020). Co-author of 79 scientific articles in indexed journals (40 as first, last or corresponding author). Publications 2009-2020: 49 (23 as first, last or corresponding author). Book chapters: 10. Direction of doctoral theses: 4. ISI Web of Science bibliometric analysis (December 06, 2020): **h index:** 30; Total number of citations: 2983; Average number of citations per item: 35.23.

## Part C. RELEVANT ACCOMPLISHMENTS

### C.1. Most important publications in national or international peer-reviewed journals, books and conferences

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 **Scientific paper.** Valhondo, Isabel; Hassouneh, Fakhri; Lopez-Sejas, Nelson; et al; Tarazona, Raquel. (17/17). 2020. Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia *CANCERS*. 12. <https://doi.org/10.3390/cancers12082171>
- 2 **Scientific paper.** Tarazona, Raquel; Lopez-Sejas, Nelson; Guerrero, Beatriz; et al; Solana, Rafael. (1/11). 2020. Current progress in NK cell biology and NK cell-based cancer immunotherapy *CANCER IMMUNOLOGY IMMUNOTHERAPY*. 69. ISSN 0340-7004. <https://doi.org/10.1007/s00262-020-02532-9>
- 3 **Scientific paper.** Beatriz Sanchez-Correa; Isabel Valhondo; Fakhri Hassouneh; et al;. (13/13). 2019. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. *Cancers*. 11-6.
- 4 **Scientific paper.** Beatriz Sanchez-Correa; Nelson Lopez-Sejas; Esther Duran; Fernando Labella; Corona Alonso; Rafael Solana; Raquel Tarazona. (7/7). 2019. Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy. *Cancer Immunology Immunotherapy*. 68-5, pp.861-870.
- 5 **Scientific paper.** Sánchez Correa, B.; Bergua, JM.; Pera, A.; et al; Tarazona, R. (AC). (9/9). 2017. In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients. *Frontiers in Immunology*. 8, pp.931.
- 6 **Scientific paper.** Tarazona, R.; Duran, E.; Solana, R.(1/3). 2016. Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy. *Frontiers in immunology*. 6, pp.649. ISSN 1664-3224.
- 7 **Scientific paper.** Sanchez Correa, B.; Campos, C.; Pera, A.; et al; Tarazona, R.(11/11). 2016. Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies? *Cancer immunology, immunotherapy*. 65-4, pp.453-516. ISSN 1432-0851.
- 8 **Scientific paper.** Solana, R.; Campos, C.; Pera, A.; Tarazona, R.(4/4). 2014. Shaping of NK cell subsets by aging. *Current opinion in immunology*. 29, pp.56-61. ISSN 1879-0372. WOS (9)
- 9 **Scientific paper.** Sanchez Correa, B.; Bergua, JM.; Campos, C.; et al; Tarazona, R.(10/10). 2013. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. *Cytokine*. 61-3, pp.885-976. ISSN 1096-0023. WOS (17)

- 10 Scientific paper.** Sanchez Correa, B.; Gayoso, I.; Bergua, JM.; Casado, JG.; Morgado, S.; Solana, R.; Tarazona, R.(2/37). 2012. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. *Immunology and cell biology*. 90-1, pp.109-124. ISSN 1440-1711. WOS (32)

### C.3. Research projects and contracts

- 1 Project.** Caracterización fenotípica y funcional de células NK “tipo memoria” dirigidas frente al cáncer: Análisis in vitro de las interacciones con células tumorales en un modelo 3D.. Junta de Extremadura. Raquel Tarazona. (Universidad de Extremadura). 17/06/2021-16/06/2024.
- 2 Project.** SAF2017-87538-R, Células citotóxicas NK y CIK en pacientes con leucemia mieloide aguda: análisis del eje DNAM-1/TIGIT y otros checkpoints para su aplicación en inmunoterapia personalizada.. Ministerio de Ciencia e Innovación. Universidades. Raquel Tarazona. (Universidad de Extremadura). 01/01/2018-31/12/2020. 96.800 €.
- 3 Project.** IB16164, Identificación de biomarcadores para el diseño de protocolos de inmunoterapia antitumoral basada en células NK. Junta de Extremadura. Raquel Tarazona. (Universidad de Extremadura). 03/06/2017-02/06/2020. 148.997,2 €. Co-ordinator. Investigador principal
- 4 Project.** SAF2013-46161-R, Caracterización de células Natural Killer y del perfil de miRNAs en pacientes de leucemia mieloide aguda como indicadores de la evolución clínica.. Ministerio de Economía y Competitividad. Raquel Tarazona. (Universidad de Extremadura). 01/01/2014-31/12/2016. 96.796 €.
- 5 Project.** LABPOLE, Large Animal Biopole. FEDER; Ministerio de Economía y Competitividad. Jesús Ventanas. (Universidad de Extremadura). 17/04/2014-31/12/2015. 4.724.407 €.
- 6 Project.** SAF2009-09711, Alteraciones fenotípicas y funcionales de las células NK en enfermedades hematológicas malignas. Interacción de células NK con células dendríticas. SAF2009-09711. Ministerio de Ciencia e Innovación. Raquel Tarazona. (Universidad de Extremadura). 01/01/2010-31/12/2013. 120.000 €.
- 7 Contract.** Estudio de la respuesta inmune celular en corderos vacunados con *Pasteurella SPP*. EA Group. Raquel Tarazona. 25/10/2017-25/10/2018. 10.000 €.

### C.4. Activities of technology / knowledge transfer and results exploitation

Javier García Casado; Raquel Tarazona; Olga de la Rosa. EP20120723442. Cell populations having immunoregulatory activity, method for isolation and uses PCT/EP2012/059313 18/05/2012. TIGENIX.